Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Xiangzhong, Xue"'
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
BackgroundThis study assessed and compared the frequency and type of adverse events (AEs) of the Pfizer-BioNTech, Moderna, and Janssen coronavirus disease 2019 (COVID-19) vaccines reported in the Vaccine Adverse Event Reporting System (VAERS).Methods
Externí odkaz:
https://doaj.org/article/d3a16ecf4a024c1a9528497832a0d8a2
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 28:1046-1052
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62ac4f250290de7e31fcfde6f38edce7
https://doi.org/10.18553/jmcp.2022.28.9.1046
https://doi.org/10.18553/jmcp.2022.28.9.1046
By 8 September 2022, 10 biological monoclonal antibody (mAb) biosimilar products for cancer treatment had been approved and marketed in the United States (US). This study examined adverse event (AE) reporting patterns and disproportionate reporting s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb0cec7f67f44d9a23d9f1b760219a00
Adverse event reporting of marketing biosimilar and biological monoclonal antibody cancer treatments
Autor:
Xiangzhong Xue, X., Qian, J.
Publikováno v:
In Research in Social and Administrative Pharmacy March 2023 19(3)
Adverse event reporting of marketing biosimilar and biological monoclonal antibody cancer treatments
Autor:
X. Xiangzhong Xue, J. Qian
Publikováno v:
Research in Social and Administrative Pharmacy. 19:5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b1434f684a0d34a792e664c025a9088
https://doi.org/10.1016/j.sapharm.2022.07.028
https://doi.org/10.1016/j.sapharm.2022.07.028